Diagnosis, combined treatment, and long-term follow-up of a thymoma patient

Thymic neoplasms account for 20 – 25% of primary mediastinal tumors. Nonspecific clinical symptoms are often associated with delayed diagnosis of thymoma, leading to a distinctive problem of late diagnosis. Nowadays, surgical removal of the tumor is the method of choice for thymoma treatment. Combination treatment is indicated in the case of an unresectable tumor. Modern therapy (various combinations of anticancer drugs) helps reduce neoplasm size, stop metastasis, and maintain good quality of life in patients with thymoma.

Aim. The presented clinical case of type B3 thymoma (with invasion into surrounding organs and metastatic pleura) is characterized by a long asymptomatic period of the disease, the onset of symptoms after suffering COVID-19 (COronaVIrus Disease 2019) and successful long-term polychemotherapy. The causes of late diagnosis, as well as insufficient oncologic vigilance in evaluating the results of laboratory and instrumental tests, are discussed based on this clinical case.

Conclusion. A correct diagnosis, as well as successful treatment, requires a multidisciplinary approach involving physicians from different specialties – general practitioners, oncologists, surgeons, radiologists, and morphologists.

1. Barbolina T.D., Bychkov M.B., Allakhverdiyev A.K. et al. [Practical recommendations for drug treatment of thymus tumors (thymomas and thymic cancer). Zlokachestvennye opukholi. 2020; 10 (3s2-1): 603–614. Available at: https://rosoncoweb.ru/standarts/RUSSCO/2020/2020-35.pdf (in Russian).

2. Robinson S.P., Akhondi Y. Thymoma. In: StatPearls [Internet].Treasure Island (FL): StatPearls Publishing; 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK559291/

3. Yıldırım F., Mutlu M.Y., İçaçan OC., Bes C. Dermatomyositis associated with thymoma: a case report and literature review. Clin. Ter. 2023; 174 (2): 115–120. DOI: 10.7417/CT.2023.2506.

4. Álvarez-Velasco R., Gutiérrez-Gutiérrez G., Trujillo J.C. et al. Clinical characteristics and outcomes of thymoma-associated myasthenia gravis. Eur. J. Neurol. 2021; 28 (6): 2083–2091. DOI: 10.1111/ene.14820.

5. Liao C.H., Lyu S.Y., Chen Y.C. et al. Thymoma-related paraneoplastic syndrome mimicking reactive arthritis. Medicina. 2021, 57 (9): 932. DOI: 10.3390/medicina57090932.

6. Hung C.T., Tsai T.F., Chen J.S. et al. Thymoma-associated multiorgan autoimmunity. BMJ Case Rep. 2019; 12 (8): e229163. DOI: 10.1136/bcr-2018-229163.

7. Suzuki M., Watari T. Thymoma-associated pure red cell aplasia following femoral neck fracture. Cureus. 2022; 14 (2): e21836. DOI: 10.7759/cureus.21836.

8. Padda S.K., Yao.X., Antonicelli A. et al. Paraneoplastic syndromes and thymic malignancies: an examination of the International thymic malignancy interest group retrospective database. J. Thorac. Oncol. 2018; 13 (3): 436–446. DOI: 10.1016/j.jtho.2017.11.118.

9. Roden A.C. Mediastinum: Thymoma. PathologyOutlines.com, Inc, 2023. Available at: https://www.pathologyoutlines.com/topic/mediastinumthymoma.html

10. Aleksandrov O.A., Ryabov A.B., Pikin O.V. Thymoma (review of the literature). Sibirskiy onkologicheskiy zhurnal. 2017; 16 (4): 76–83. DOI: 10.21294/1814-4861-2017-16-4-76-83 (in Russian).

11. Brito‑Dellan N., Tsoukalas N., Font C. Thrombosis, cancer, and COVID‑19. Sup. Care Cancer. 2022; 30 (10): 8491–8500. DOI: 10.1007/s00520-022-07098-z.

12. Parshin V.D., Mirzoyan O.S., Titov V.A. et al. [Surgical treatment of giant thymoma complicated by intrathoracic compression syndrome]. Khirurgiya. Zhurnal im.N.I.Pirogova. 2019; (12): 132–136. DOI: 10.17116/hirurgia2019121132 (in Russian).

13. Chkhikvadze V.D., Kolesnikov P.G., Kovbasyuk D.A. [A rare case of torpid recurrent thymoma]. Onkologiya. Zhurnal im. P.A.Gertsena. 2019; 8 (1): 45–47. DOI: 10.17116/onkolog2019801145 (in Russian).

14. Ak N., Toker A., Kara M. et al. Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of tertiary cancer center. Turk. J. Thorac. Cardiovasc. Surgery. 2021; 29 (4): 487–495. DOI: 10.5606/tgkdc.dergoso.2021/20529.

15. Wrona E., Debska-Szmich S., Pastuszka M. et al. Remission of thymoma on steroid therapy in a patient with atypical thymoma-associated multiorgan autoimmunity: a case report and literature review. Front. Immunol. 2021; 12: 584703. DOI: 10.3389/fimmu.2021.584703.

16. Sato J., Satouchi S., Itoh S. et al. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicenter, phase 2 trial. Lancet Oncol. 2020; 21 (6): 843–850. DOI: 10.1016/S1470-2045(20)30162-5.

17. Remon J., Girard N., Novello S. et al. PECATI: a multicentric, open-label, single-arm phase II study to evaluate the efficacy and safety of pembrolizumab and lenvatinib in pretreated B3-thymoma and thymic carcinoma patients. Clin. Lung Cancer. 2022; 23 (3): e243–246. DOI: 10.1016/j.cllc.2021.07.008.